Join Growin Stock Community!

Orasure technologies, inc.OSUR.US Overview

US StockHealthcare
(No presentation for OSUR)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

OSUR AI Insights

OSUR Overall Performance

OSUR AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

OSUR Recent Performance

-5.24%

Orasure technologies, inc.

0.05%

Avg of Sector

-0.31%

S&P500

OSUR PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

OSUR Key Information

OSUR Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

OSUR Profile

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND genomics laboratory services. In addition, the company provides ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; offers Colli-Pee collection device for the volumetric collection of first void urine; and manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the academic research and commercial applications, including ancestry, disease risk management, lifestyle, and animal testing. Further, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.

Price of OSUR

OSUR FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

OSUR Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.94
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
2.00
PB Ratio
0.61
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
41.90%
Net Margin
-59.76%
Revenue Growth (YoY)
-38.10%
Profit Growth (YoY)
-39.29%
3-Year Revenue Growth
-39.87%
3-Year Profit Growth
-39.52%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.94
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
2.00
PB Ratio
0.61
Price-to-FCF
-
Gross Margin
41.90%
Net Margin
-59.76%
Revenue Growth (YoY)
-38.10%
Profit Growth (YoY)
-39.29%
3-Year Revenue Growth
-39.87%
3-Year Profit Growth
-39.52%

  • When is OSUR's latest earnings report released?

    The most recent financial report for Orasure technologies, inc. (OSUR) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating OSUR's short-term business performance and financial health. For the latest updates on OSUR's earnings releases, visit this page regularly.

  • What is the operating profit of OSUR?

    According to the latest financial report, Orasure technologies, inc. (OSUR) reported an Operating Profit of -16.85M with an Operating Margin of -62.97% this period, representing a decline of 35.71% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is OSUR's revenue growth?

    In the latest financial report, Orasure technologies, inc. (OSUR) announced revenue of 26.76M, with a Year-Over-Year growth rate of -28.53%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does OSUR have?

    At the end of the period, Orasure technologies, inc. (OSUR) held Total Cash and Cash Equivalents of 199.28K, accounting for 0 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does OSUR go with three margins increasing?

    In the latest report, Orasure technologies, inc. (OSUR) did not achieve the “three margins increasing” benchmark, with a gross margin of 40.98%%, operating margin of -62.97%%, and net margin of -72.06%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess OSUR's profit trajectory and future growth potential.

  • Is OSUR's EPS continuing to grow?

    According to the past four quarterly reports, Orasure technologies, inc. (OSUR)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.27. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of OSUR?

    Orasure technologies, inc. (OSUR)'s Free Cash Flow (FCF) for the period is -9.92M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 2,758.21% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of OSUR?

    The latest valuation data shows Orasure technologies, inc. (OSUR) has a Price-To-Earnings (PE) ratio of -2.25 and a Price/Earnings-To-Growth (PEG) ratio of -0.05. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.